Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranexa for Diabetic Peripheral Neuropathic Pain
NCT02156336Phase 4Terminated
- Sponsor
- Horizons International Peripheral Group
- Start
- May 2014
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ranolazine in diabetic polyneuropathy (DPN), sponsored by Horizons International Peripheral Group. Primary endpoint: Numeric Rating Scale reduction at 6 weeks. Started May 2014; status: terminated.
02
Drugs
ranolazine
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT02156336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02156336.